#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.

Peter Attia

Jul 13, 2026

Episode description

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer's disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer's disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing in asymptomatic patients, the benefits and risks of anti-amyloid therapies such as lecanemab and donanemab, and strategies for minimizing treatment-related complications. Gayatri also examines why some patients may stabilize or even improve with individualized care, the overlap among different dementia syndromes, and the relationship between menopause, estrogen, and cognition—including her concept of menopause-related cognitive impairment. Finally, she discusses how advances in early detection, AI-assisted monitoring, targeted therapies, and precision medicine are reshaping the future of dementia care.

We discuss:

Gayatri's training and clinical focus, why dementia is a spectrum disease, and how personalized treatment is changing Alzheimer's care [3:45];
How Alzheimer's disease fits within the broader spectrum of dementia: diagnosis, biomarkers, and early pathophysiology [7:15];
The emerging role of neuroinflammation and viral infections in Alzheimer's disease [13:30];
Gayatri's comprehensive approach to evaluating cognitive decline in high-functioning patients [17:45];
Why forgetting names is usually normal and when word-finding problems become concerning [29:00];
Why women are at higher risk for Alzheimer's disease and how menopause influences cognition [33:45];
The promise and limitations of blood-based biomarkers for diagnosing Alzheimer's disease [40:15];
When preclinical Alzheimer's screening is appropriate and how to interpret positive biomarker results [45:00];
Case study: early Alzheimer's prevention in a highly-functional woman in her 50s with two copies of APOE4 [47:15];
A

Mindsip insights from this episode:

Recognize dementia as a spectrum disorder for better understanding

Dementia, particularly Alzheimer's, is not an all-or-nothing disease but a spectrum disorder that can range from very mild impairment that doesn't worsen to severe, rapid deterioration.

#Alzheimer's

#dementia

Interpret blood tests carefully to avoid Alzheimer's misdiagnosis

Blood tests for Alzheimer's are often standardized against amyloid PET scans, which can be positive in up to 44% of healthy 90-year-olds, leading to potential misdiagnosis if not paired with other biomarkers and clinical symptoms.

#Alzheimer's

#blood-test

Differentiate menopause-related cognitive impairment from Alzheimer's for effective treatment

A condition termed 'menopause-related cognitive impairment' can present with symptoms identical to early Alzheimer's disease but may be treatable with hormone replacement or other interventions.

#Alzheimer's

#menopause

Utilize off-label TMS to support dementia patients' brain function

Targeted Transcranial Magnetic Stimulation (TMS) is used off-label to stimulate specific brain circuits and help maintain function in patients with dementia, particularly those with language problems.

#dementia

#therapy

Differentiate Lewy body dementia from Parkinson's disease tremor

A key clinical distinction is that patients with Lewy Body dementia typically do not present with the classic 'pill-rolling' rest tremor seen in Parkinson's disease.

#dementia

#Parkinson's

Implement slow titration protocol for safer anti-amyloid drug use

A very slow titration protocol for anti-amyloid drugs can drastically reduce the risk of side effects like brain swelling and bleeding from over 40% to around 4%, even in high-risk ApoE4/4 patients.

#cancer

#side-effects

Implement personalized multimodal treatment to stabilize Alzheimer's condition

Contrary to conventional wisdom, some patients with biomarker-confirmed Alzheimer's disease can see their condition stabilize or even improve with a personalized, multimodal treatment strategy.

#Alzheimer's

#personalized-health

Recognize inflammation's role in Alzheimer's onset

The Alzheimer's disease process may begin with changes in inflammatory pathways that predate the deposition of amyloid in the brain by a significant amount of time.

#Alzheimer's

#inflammation

Recognize normal name forgetfulness versus significant memory issues

The brain is not designed to remember an endless amount of names, but having trouble recalling common nouns like 'chair' or 'book' is a more significant problem.

#cognition

Peter Attia

Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)

#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss

#397 ‒ Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, and emerging treatments | Renato Tomioka, M.D., Ph.D.

#396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategy

#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.